Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 589.50 GBp
Change Today +4.50 / 0.77%
Volume 405.5K
ABC On Other Exchanges
As of 11:35 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

abcam plc (ABC) Snapshot

585.00 GBp
Previous Close
585.00 GBp
Day High
592.00 GBp
Day Low
577.50 GBp
52 Week High
07/28/15 - 593.00 GBp
52 Week Low
10/16/14 - 356.25 GBp
Market Cap
Average Volume 10 Days
0.18 GBp
Shares Outstanding
8.79 GBp
Dividend Yield
Current Stock Chart for ABCAM PLC (ABC)

Related News

No related news articles were found.

abcam plc (ABC) Related Businessweek News

No Related Businessweek News Found

abcam plc (ABC) Details

Abcam plc, through its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies, biochemicals, isotype controls, flow cytometry multi-color selectors, kits, loading controls, lysates, peptides, proteins, slides, tags and cell markers, tools and reagents, and immunoassays. Its products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, drug discovery products and services, epigenetics and nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company sells its products primarily through the Internet. Abcam plc was founded in 1998 and is based in Cambridge, the United Kingdom.

800 Employees
Last Reported Date: 03/9/15
Founded in 1998

abcam plc (ABC) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: 185.0K GBP
Co-Founder and Deputy Chairman
Total Annual Compensation: 628.0K GBP
Chief Financial Officer, Director and Member ...
Total Annual Compensation: 478.0K GBP
Chief Operating Officer, Director and Member ...
Total Annual Compensation: 481.0K GBP
Compensation as of Fiscal Year 2014.

abcam plc (ABC) Key Developments

Abcam Plc Announces Executive Appointments Effective from July 6, 2015

Abcam plc announced that it has appointed Suzanne Smith in the new role of Chief Legal Officer and Company Secretary, based at Abcam's headquarters in Cambridge, UK, effective from July 6, 2015. Accordingly, Jeff Iliffe will resign from the role of Company Secretary with effect from the same date. Suzanne will take responsibility for Abcam's licensing, legal, compliance and company secretary activities. The new role has been created in order to help Abcam achieve its global growth objectives, supporting the Company's partnership and acquisition goals. Suzanne brings a wealth of experience to Abcam with 20 years' global legal, business and leadership experience within the life science industry. She previously held the role of executive director, legal at Actavis plc, where she had responsibility for the leadership of the legal function internationally. Her prior roles include legal director at Genzyme Therapeutics Ltd, general counsel at Phoqus Pharmaceuticals plc and group legal counsel and company secretary at LGC Ltd. Suzanne is a qualified solicitor and holds an LLB law degree from the University of Exeter and an MBA from the Open University.

Abcam plc Unveils New Multiplex miRNA Profiling Assays

Abcam plc unveiled new multiplex miRNA profiling assays for high-throughput validation of miRNA biomarkers, based on its new Firefly particle technology. The new Multiplex Cellular miRNA Assay and Multiplex Circulating miRNA Assay allow researchers to rapidly and cost-effectively profile up to 68 miRNAs in each well of a 96-well plate, with readout on a standard flow cytometer. These assays offer an easier workflow for larger sample numbers compared to alternative methods such as qPCR, microarray and sequencing, which can be resource intensive or require challenging data analysis. The Multiplex Circulating miRNA assay enables profiling of miRNAs from small volumes of crude biofluids including serum and plasma, with no need for RNA purification, while the Multiplex Cellular miRNA Assay is optimized to work with purified RNA. The Multiplex Circulating miRNA Assay is particularly suited for studies targeting low-abundance miRNAs or where the amount of each sample is limiting. Customers can chose between fixed panels targeting specific disease areas or can customize their own panel. Abcam also offers a sample profiling service to enable researchers without in-house resources to obtain profiles with this technology. Analysis software provided by Abcam efficiently translates the raw data from the flow cytometer into a miRNA profile and does not require special bioinformatics expertise.

Abcam Plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended December 31, 2014

Abcam Plc reported unaudited consolidated earnings results for the six months ended December 31, 2014. For the period, the company reported revenue of £66.746 million against £61.950 million a year ago. Operating profit was £21.880 million against £21.121 million a year ago. Profit before tax was £22.060 million against £21.225 million a year ago. Profit attributable to owners of the parent was £17.656 million or 8.79 pence diluted per share against £16.501 million or 8.24 pence diluted per share a year ago. Net cash inflow from operating activities was £18.433 million against £15.111 million a year ago. Purchase of property, plant and equipment was £2.553 million against £2.007 million a year ago. Purchase of intangible assets was £0.551 million against £2.087 million a year ago. Adjusted diluted EPS increased by 7.3% to 9.38 pence per share compared to first half of 2014 of 8.74 pence, reflecting a reduced effective tax rate.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABC:LN 589.50 GBp +4.50

ABC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ABC.
View Industry Companies

Industry Analysis


Industry Average

Valuation ABC Industry Range
No financial data is available for ABC.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABCAM PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at